As the discovery of new immunohistochemical markers is of particular interest for PanNETs, we decided to explore CD200 expression in pancreatic tumors that represent their most important differential diagnosis: solid pseudopapillary neoplasms (SPNs), acinar cell carcinomas (ACs), and pancreatoblastomas (PBs). This evidence concerns the gene CD200 and acinar cell carcinoma.